Tyrphostin Ag 879

Tyrphostin Ag 879

SCHEMBL607702

CC(C)(C)c1cc(/C=C(/C#N)C(N)=S)cc(C(C)(C)C)c1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 1.00
KMT2A Q03164 8/20 1.00
ALDH1A1 P00352 8/20 1.00
MEN1 O00255 7/20 1.00
BLM P54132 6/20 1.00
HPGD P15428 6/20 1.00
TDP1 Q9NUW8 6/20 1.00
KDM4E B2RXH2 5/20 1.00
CYP3A4 P08684 4/20 1.00
TSHR P16473 4/20 1.00
HSD17B10 Q99714 4/20 1.00
RECQL P46063 4/20 1.00
ERBB2 P04626 3/20 1.00
SMN1; SMN2 Q16637 3/20 1.00
RGS12 O14924 3/20 1.00
CYP1A2 P05177 3/20 1.00
CYP2C9 P11712 3/20 1.00
ALOX15 P16050 3/20 1.00
NFKB1 P19838 3/20 1.00
CYP2C19 P33261 3/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tyrphostin Ag 879 SCHEMBL607703 1.00 MAPT (1.00) MAPTKMT2AALDH1A1MEN1BLM
Tyrphostin Ag 879 SCHEMBL607701 1.00 MAPT (1.00) MAPTKMT2AALDH1A1MEN1BLM
SCHEMBL25736022 0.88 MEN1 (0.78) MAPTKMT2AALDH1A1MEN1BLM
SCHEMBL11093690 0.86 EGFR (1.00) MAPTKMT2AALDH1A1MEN1BLM
SCHEMBL20333049 0.86 MEN1 (0.76) MAPTKMT2AALDH1A1MEN1BLM
SCHEMBL11093692 0.86 EGFR (1.00) MAPTKMT2AALDH1A1MEN1BLM
SCHEMBL8346188 0.81 EGFR (0.76) MAPTKMT2AALDH1A1MEN1BLM
SCHEMBL6286531 0.81 MAPT (0.68) MAPTKMT2AALDH1A1MEN1BLM
SCHEMBL6278934 0.81 MAPT (0.68) MAPTKMT2AALDH1A1MEN1BLM
SCHEMBL3244723 0.80 EGFR (0.74) MAPTKMT2AALDH1A1MEN1BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5981569-A CAPABLE OF MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION AND PARTICULARLY KDR/FLK-1 RECEPTOR SIGNAL TRANSDUCTION IN ORDER TO REGULATE AND/OR MODULATE VASCULOGENESIS AND ANGIOGENESIS; TREATMENT OF CANCER, DIABETES, HEMANGIOMA YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1999-11-09 US claimed
US-9353218-B2 Kit for multifunctional compounds forming crosslinked biomaterials ANGIOTECH PHARMACEUTICALS, INC. 2016-05-31 US disclosed
US-9326934-B2 Drug delivery from rapid gelling polymer composition ANGIOTECH INTERNATIONAL AG 2016-05-03 US disclosed
EP-2181704-B1 Drug delivery from rapid gelling polymer composition ANGIOTECH INT AG (CH) 2015-05-06 EP disclosed
US-20130289235-A1 MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE ANGIOTECH PHARMACEUTICALS, INC. (CA) 2013-10-31 US disclosed
US-8486437-B2 Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use ANGIOTECH PHARMACEUTICALS (US), INC. (US) 2013-07-16 US disclosed
US-8481073-B2 Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use ANGIODEVICE INTERNATIONAL GMBH (CH) 2013-07-09 US disclosed
US-8460708-B2 Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use ANGIODEVICE INTERNATIONAL GMBH (CH) 2013-06-11 US disclosed
US-20130012683-A1 MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE ANGIOTECH PHARMACEUTICALS (US), INC. (US) 2013-01-10 US disclosed
US-8303973-B2 Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use ANGIOTECH PHARMACEUTICALS (US), INC. (US) 2012-11-06 US disclosed
WO-2004060405-A2 TISSUE REACTIVE COMPOUNDS AND COMPOSITIONS AND USES THEREOF ANGIOTECH INTERNATIONAL AG (CH) 2004-07-22 WO disclosed
JP-2000026393-A COMPOUND FOR THERAPY OF DISEASE RELATING TO ANGIOPLASTY AND/OR ANGIOGENESIS SUUGEN INC 2000-01-25 JP disclosed
US-5981569-A CAPABLE OF MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION AND PARTICULARLY KDR/FLK-1 RECEPTOR SIGNAL TRANSDUCTION IN ORDER TO REGULATE AND/OR MODULATE VASCULOGENESIS AND ANGIOGENESIS; TREATMENT OF CANCER, DIABETES, HEMANGIOMA YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1999-11-09 US disclosed
EP-0748219-A4 COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS SUGEN INC (US) 1999-06-16 EP disclosed
US-5849742-A Compounds for the treament of disorders related to vasculogenesis and/or angiogenesis SUGEN INC. (US) 1998-12-15 US disclosed
US-5792771-A FOR TREATING TUMORS, VASCULAR SYSTEM DISORDERS, DIABETES, DIABETIC RETINOPATHY, RHEUMATOID ARTHRITIS AND HEMANGIOMA SUGEN, INC. (US) 1998-08-11 US disclosed
US-5763441-A ADMINISTERING TO THE PATIENT SUFFERING FROM DIABETES, GLIOMA, HEMANGIOMA, KAPOSI'S SARCOMA, OVARIAN/BREAST/PANCREATIC/COLON AND PROSTATE CANCER A BENZO(G)QUINOXALINE COMPOUNDS SUGEN, INC. (US) 1998-06-09 US disclosed
US-5712395-A BENZO(G)QUINOXALINE YISSUM RESEARCH DEVELOPMENT CORP. (IL) 1998-01-27 US disclosed
EP-0748219-A1 COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS Sugen, Inc. (US) 1996-12-18 EP disclosed
WO-1995021613-A1 COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS SUGEN, INC. (US) 1995-08-17 WO disclosed